Skip to main content
Cinclus Pharma Holding AB logo

Cinclus Pharma Holding AB — Investor Relations & Filings

Ticker · CINPHA ISIN · SE0020388577 LEI · 549300TJBPSNZ3DO6B42 ST Manufacturing
Open in API
Filings indexed 68 across all filing types
Latest filing 2025-05-22 AGM Information
Country SE Sweden
Listing ST CINPHA

About Cinclus Pharma Holding AB

https://cincluspharma.com/

Cinclus Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing treatments for gastric acid-related diseases. The company's lead drug candidate is linaprazan glurate, a Potassium-Competitive Acid Blocker (PCAB) in late-stage clinical development. This therapeutic is being developed to treat gastroesophageal reflux disease (GERD), particularly severe erosive GERD, and for the eradication of Helicobacter pylori infections. Linaprazan glurate represents a next-generation approach, aiming to provide superior clinical efficacy and a more beneficial pharmacokinetic profile compared to traditional Proton Pump Inhibitors (PPIs). The goal is to address the unmet medical needs of patients who do not achieve sufficient disease control with current therapies.

Recent filings

Filing Released Lang Actions
Beslut vid årsstämma i Cinclus Pharma Holding AB (publ) den 22 maj 2025
AGM Information Classification · 98% confidence The document is titled "BESLUT VID ÅRSSTÄMMA I CINCLUS PHARMA HOLDING AB (PUBL) DEN 22 MAJ 2025" which translates to "DECISION AT THE ANNUAL GENERAL MEETING IN CINCLUS PHARMA HOLDING AB (PUBL) ON MAY 22, 2025". The content details decisions made regarding board members, auditors, remuneration, dividend disposition, and authorization for new share issues, all typical items discussed and voted upon at an Annual General Meeting (AGM). Although it reports the decisions, the primary context is the AGM itself. The definition for AGM Information (AGM-R) covers "Presentations and materials shared during the Annual General Meeting (AGM)". Since this document explicitly details the resolutions passed at the AGM, AGM-R is the most appropriate classification. It is not a proxy statement (PSI) as it reports the results, not solicits votes, and it is not a DVA as it covers the entire meeting's decisions, not just the voting results summary.
2025-05-22 Swedish
Resolutions at the Annual General Meeting in Cinclus Pharma Holding AB (publ) on 22 May 2025
AGM Information Classification · 99% confidence The document explicitly details the 'RESOLUTIONS AT THE ANNUAL GENERAL MEETING IN CINCLUS PHARMA HOLDING AB (PUBL) ON 22 MAY 2025'. It covers decisions made regarding the discharge of liability, election of the Board of Directors and auditors, director fees, allocation of results (no dividend), approval of the remuneration report, and authorization for new share issues. These topics are central to the proceedings and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information). The document is not a proxy statement (PSI) or a general regulatory filing (RNS), but a summary of the meeting's results.
2025-05-22 English
Cinclus Pharma ingår partnerskap med Zentiva för att kommersialisera linaprazan glurate i Europa
Regulatory Filings Classification · 98% confidence The document announces a strategic alliance and licensing agreement between Cinclus Pharma and Zentiva regarding the commercialization of linaprazan glurate in Europe. It details financial terms (upfront payment, milestones, royalties) and includes an invitation to a webcast/conference call to discuss the news. The final section explicitly mentions that the information is being made public according to the EU Market Abuse Regulation and provides links to attached files (PDFs). This structure—a press release announcing a significant corporate event (partnership/licensing deal) and providing details on an accompanying call—is characteristic of a general regulatory announcement or press release, rather than a formal periodic report (like 10-K or IR) or a specific financial filing like an Earnings Release (ER). Since it is a significant, mandatory disclosure under market abuse rules that doesn't fit the other specific categories (like M&A, Capital Change, or Director's Dealing), the most appropriate classification is the general regulatory announcement fallback, RNS (Regulatory Filings). The document length (7921 chars) is substantial enough to be the primary announcement itself, not just a brief RPA.
2025-05-22 Swedish
Cinclus Pharma Partners with Zentiva to Commercialize Linaprazan Glurate in Europe
Regulatory Filings Classification · 95% confidence The document announces a strategic alliance and licensing agreement between Cinclus Pharma and Zentiva regarding the commercialization of linaprazan glurate in Europe. This is a significant business development and partnership announcement. It is not a full Annual Report (10-K), an Interim Report (IR), or a standard Earnings Release (ER). It details a transaction (licensing/partnership) which often falls under Capital/Financing Update (CAP) or a general Regulatory Filing (RNS). Since it describes a major commercial deal structure involving upfront payments and milestones, it is most closely related to financing/capital structure changes or a significant corporate event announcement. Given the options, 'Capital/Financing Update (CAP)' is a plausible fit for a major deal structuring, but 'Regulatory Filings (RNS)' is the most appropriate general category for significant, non-standard corporate news releases that don't fit the specific financial report types, especially when the text ends with a link to a PDF attachment and a statement about EU Market Abuse Regulation disclosure. However, major partnership announcements detailing deal value and milestones are often classified as 'Capital/Financing Update (CAP)' if they involve significant financial terms, or sometimes as 'Regulatory Filings (RNS)' if they are primarily disclosure mandated by market rules. Since this is a major commercial agreement announcement, and not a direct financing round, RNS is the safest fallback for a significant corporate event disclosure. Upon review, this type of strategic alliance announcement is often categorized under general regulatory disclosure rather than specific capital raising (CAP). I will use RNS as the best fit for a mandatory market disclosure of a strategic partnership.
2025-05-22 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport januari – mars 2025' (Interim Report January – March 2025) for Cinclus Pharma Holding AB. It contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and notes for the first quarter of 2025. It is a full quarterly report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-20 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim Report January – March 2025' for Cinclus Pharma Holding AB. It contains comprehensive financial statements, including consolidated income statements, statements of financial position, cash flow statements, and notes to the financial statements. It also includes a CEO statement, management discussion of significant events, and key performance measures. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2025
2025-05-20 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.